Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Low dose CT detected interstitial lung abnormalities in a population with low asbestos exposure

The use of low dose CT (LDCT) chest is becoming more widespread in occupationally exposed populations. There is a knowledge gap as to heterogeneity in severity and the natural course of asbestosis after low levels of exposure. This study reports the characteristics of LDCT-detected interstitial lung abnormalities (ILA).

Lung problems continue into childhood for premmie babies

New research from Perth’s The Kids Research Institute Australia shows that babies born premature continue to have lung problems well into childhood.

ABCA3 lung disease in an ex 27 week preterm infant responsive to systemic glucocorticosteroids

This is a case of ABCA3 lung disease that demonstrated improvement after systemic glucocorticosteroid administration

Fighting lung disease

Culturally secure intervention to facilitate medical follow up for Aboriginal children, after being hospitalised with chest infections, have proven to improve long-term lung health outcomes.

Arsenic in drinking water linked to lung disease

The Kids research has uncovered likely mechanisms for the link between arsenic in drinking water and higher risk of developing chronic lung disease.

Early cystic fibrosis lung disease

This paper is about lung disease in patients with cyctic Fibrosis and prevention strategies to slow the onset of lung disease.

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases Antisense oligonucleotides (AOs) are an emerging

Altered lung structure and function in mid-childhood survivors of very preterm birth

To obtain comprehensive data on lung structure and function in mid-childhood from survivors of preterm birth.

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases

Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient's genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design.